Evidence map›Paper›PMID 39320906›Full record

ArticleFuture oncology (London, England)2024

Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study.

Wonseok Kang, Yoon Jun Kim, Seung Up Kim, Yeon Seok Seo, Jin-Wook Kim, Ji Hoon Kim, Soo Young Park, Yang-Hyun Baek, Kang Mo Kim, Hae Lim Lee and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wonseok KangDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID 0000-0001-9578-8424
Yoon Jun KimDepartment of Internal Medicine & Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seung Up KimDepartment of Internal Medicine, Yonsei Liver Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Yeon Seok SeoDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Jin-Wook KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Ji Hoon KimDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Soo Young ParkDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Yang-Hyun BaekDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea.
Kang Mo KimDepartment of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hae Lim LeeDepartment of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Republic of Korea.
Ki Tae YoonDepartment of Internal Medicine, Pusan National University College of Medicine, Liver Center, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
Hyeyeong KimDepartment of Medical Oncology, Ulsan University Hospital, Ulsan, Republic of Korea.
Jae Youn CheongDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.
Jae Seok HwangDepartment of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea.
Ju Hyun KimDepartment of Internal Medicine, Gachon University of Medicine & Science, Incheon, Republic of Korea.
Kwang Min KimDepartment of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
Pil Soo SungDivision of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Jieun KimDepartment of Medical, Eisai Korea Inc., Seoul, Republic of Korea.
Do Young KimDepartment of Internal Medicine, Yonsei Liver Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

Funding

Eisai Korea
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsProduct Surveillance, PostmarketingQuinolinesAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedProtein Kinase InhibitorsRepublic of KoreaTreatment OutcomeAntineoplastic AgentslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolineseffectivenesshepatocellular carcinomaKorean populationlenvatinibreal-world practiceREFLECT trialsafety

Identifiers

PMID39320906
PMCPMC11572195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.